pISSN 2234-3806eISSN 2234-3814
Table. 2.
Antimicrobial susceptibility patterns and molecular characteristics of Bacteroides fragilis clinical isolates
| Strain | Specimen | ST | MIC (mg/L) | β-lactam resistance genes | Toxin gene | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PEN | FOX | CTT | PIP/TAZ | IMP | MEM | CLN | MOX | MET | cepA | cfxA | cfiA | bft | |||||
| 1 | Tissue | 69 | 32 | 4 | 4 | 0.25 | 0.25 | 0.12 | 0.5 | 0.06 | 1 | + | – | – | – | ||
| 2 | Pus | 105 | 64 | 2 | 4 | 0.25 | 0.25 | 0.12 | 1 | 0.5 | 1 | + | + | – | – | ||
| 3 |
Pus | 1 | 256 | 8 | 32 | 1 | 0.5 | 0.5 | 1 | 8 | 0.5 | + | + | – | bft-2 | ||
| 4 | Blood | 27 | 16 | 4 | 4 | 0.25 | 0.25 | 0.12 | 128 | 0.06 | 0.5 | + | – | – | bft-1 | ||
| 5 | Blood | 21 | 256 | 8 | 16 | 1 | 1 | 0.5 | 0.5 | 8 | 0.5 | + | + | – | – | ||
| 6 | Blood | 17 | 16 | 4 | 4 | 0.25 | 0.25 | 0.12 | 256 | 0.06 | 1 | + | – | – | – | ||
| 7 | Blood | 106 | 32 | 4 | 4 | 0.25 | 0.25 | 0.12 | 0.5 | 0.12 | 1 | + | – | – | – | ||
| 8 | Pus | 56 | 256 | 4 | 8 | 0.5 | 0.25 | 0.25 | 256 | 16 | 0.5 | + | – | – | bft-2 | ||
| 9 |
Blood | 9 | 8 | 4 | 4 | 0.25 | 0.25 | 0.12 | 2 | 0.06 | 1 | + | – | – | – | ||
| 10 |
Blood | 1 | 16 | 4 | 4 | 0.12 | 0.12 | 0.12 | 2 | 0.06 | 0.5 | + | – | – | bft-2 | ||
| 11 | Pus | 4 | 32 | 4 | 4 | 0.25 | 0.25 | 0.12 | 0.06 | 0.12 | 1 | + | – | – | – | ||
| 12 |
Blood | 10 | 32 | 8 | 4 | 0.5 | 0.25 | 0.12 | 0.5 | 0.12 | 1 | + | – | – | – | ||
| 13 | Pus | 1 | 32 | 8 | 4 | 0.25 | 0.12 | 0.12 | 1 | 0.5 | 1 | + | – | – | bft-1 | ||
| 14 | Pus | 21 | 256 | 16 | 64 | 0.25 | 0.25 | 0.25 | 256 | 0.12 | 1 | + | + | – | – | ||
| 15 | Blood | 39 | 256 | 8 | 8 | 0.25 | 0.5 | 0.25 | 256 | 0.06 | 0.5 | + | – | – | bft-3 | ||
| 16 |
Blood | 48 | 16 | 4 | 8 | 0.25 | 0.25 | 0.12 | 0.5 | 4 | 1 | + | – | – | – | ||
| 17 | Pus | 149 | 16 | 4 | 4 | 0.12 | 0.25 | 0.12 | 256 | 0.06 | 0.25 | + | – | – | bft-3 | ||
| 18 |
Blood | 146 | 128 | 8 | 32 | 0.06 | 0.25 | 0.12 | 256 | 1 | 1 | + | + | – | – | ||
| 19 | Pleural fluid | 11 | 16 | 8 | 8 | 0.12 | 0.25 | 0.06 | 4 | 0.06 | 1 | + | – | – | – | ||
| 20 | Blood | 157 | 256 | 64 | 64 | 256 | 64 | 128 | 256 | 0.06 | 2 | – | – | +, IS1187 | – | ||
| 21 | Blood | 7 | 32 | 4 | 4 | 0.25 | 0.12 | 0.12 | 0.5 | 0.06 | 0.5 | + | – | – | – | ||
| 22 | Blood | 98 | 16 | 4 | 4 | 0.25 | 0.12 | 0.12 | 0.5 | 0.06 | 1 | + | – | – | – | ||
| 23 |
Blood | 135 | 16 | 4 | 4 | 0.25 | 0.12 | 0.12 | 2 | 0.12 | 0.5 | + | – | – | bft-1 | ||
| 24 |
Blood | 120 | 256 | 8 | 8 | 0.25 | 0.25 | 0.25 | 1 | 0.06 | 1 | + | + | – | – | ||
| 25 | Blood | 122 | 32 | 16 | 8 | 8 | 4 | 8 | 1 | 4 | 0.5 | – | – | + | – | ||
| 26 | Pus | 149 | 256 | 8 | 64 | 0.25 | 0.5 | 0.25 | 0.06 | 8 | 0.25 | + | + | – | bft-1 | ||
| 27 | Tissue | 136 | 32 | 8 | 4 | 0.25 | 0.25 | 0.12 | 1 | 4 | 1 | + | – | – | – | ||
| 28 | Blood | 141 | 16 | 4 | 8 | 0.25 | 0.25 | 0.12 | 256 | 0.12 | 0.5 | + | – | – | – | ||
| 29 | Blood | 143 | 32 | 4 | 4 | 0.25 | 0.25 | 0.12 | 0.06 | 0.06 | 1 | + | – | – | – | ||
| 30 | Pus | 11 | 256 | 8 | 64 | 0.5 | 1 | 2 | 1 | 2 | 0.5 | + | + | – | – | ||
| 31 |
Blood | 79 | 16 | 16 | 16 | 2 | 0.25 | 0.25 | 0.5 | 2 | 1 | + | – | – | bft-1 | ||
| 32 | Blood | 149 | 256 | 8 | 32 | 0.25 | 0.25 | 0.25 | 256 | 0.06 | 0.25 | + | + | – | bft-1 | ||
| 33 | Blood | 11 | 256 | 8 | 8 | 0.5 | 0.5 | 0.25 | 256 | 0.06 | 1 | + | + | – | – | ||
| 34 |
Pus | 40 | 256 | 8 | 32 | 1 | 0.5 | 0.5 | 0.5 | 4 | 0.5 | + | + | – | – | ||
| 35 | Blood | 11 | 8 | 4 | 2 | 0.12 | 0.25 | 0.12 | 1 | 0.06 | 1 | + | – | – | – | ||
| 36 |
Blood | 142 | 16 | 8 | 2 | 0.25 | 0.25 | 0.12 | 0.5 | 2 | 0.5 | + | – | – | – | ||
| 37 | Tissue | 12 | 256 | 128 | 256 | 2 | 2 | 4 | 256 | 4 | 0.25 | + | + | – | – | ||
| 38 | Blood | 149 | 8 | 4 | 4 | 0.12 | 0.25 | 0.12 | 256 | 8 | 0.5 | + | – | – | bft-1 | ||
| 39 | Blood | 23 | 16 | 4 | 8 | 0.25 | 0.25 | 0.12 | 256 | 4 | 0.5 | + | – | – | – | ||
| 40 | Tissue | 87 | 256 | 4 | 16 | 0.5 | 0.25 | 0.25 | 256 | 8 | 0.5 | + | + | – | – | ||
| Resistant/positive rate (%) | 100 | 5.0 | 12.5 | 2.5 | 2.5 | 2.5 | 37.5 | 15.0 | 0 | 100 | 32.5 | 5.0 | 30.0 | ||||
*Patients with a history of anaerobic antibiotic use within 1 yr prior to admission
†Patients who died due to infection with B. fragilis.
Abbreviations: MIC, minimum inhibitory concentration; PEN, penicillin; FOX, cefoxitin; CTT, cefotetan; PIP/TAZ, piperacillin-tazobactam; IMP, imipenem; CLN, clindamycin; MOX, moxifloxacin; MET, metronidazole.
Ann Lab Med 2025;45:223~227 https://doi.org/10.3343/alm.2024.0369
© Ann Lab Med